Bloomberg News

Boston Scientific to Buy Cameron for New Heart Device in $1.35 Bln Deal

March 09, 2012

Researchers work in a clean room at the Boston Scientific Cardiovascular research and development center in Maple Grove, Minnesota, U.S. Source: Boston Scientific via Bloomberg

Researchers work in a clean room at the Boston Scientific Cardiovascular research and development center in Maple Grove, Minnesota, U.S. Source: Boston Scientific via Bloomberg

Boston Scientific Corp. (BSX) agreed to buy Cameron Health Inc. for as much as $1.35 billion to add a new type of defibrillator to bolster a shrinking market for the devices used to shock stopped hearts.

Boston Scientific, the second-biggest cardiac-device maker, will pay $150 million when the deal closes and another $150 million if Cameron’s technology called the S-ICD System wins U.S. Food and Drug Administration approval, the Natick, Massachusetts-based company said in a statement yesterday. Cameron may receive as much as $1.05 billion more based on the revenue the device generates.

Demand for defibrillators, Boston Scientific’s biggest products, has plunged since peaking in 2009 amid concerns about safety and overuse of the devices. Cameron’s defibrillator is implanted just below the skin and doesn’t attach to the heart or blood vessel with the thin, insulated wires that caused failures in other devices.

“This is probably the most major advance in the field in the last decade,” said Chief Executive Officer Hank Kucheman in a telephone interview today. “It has the potential to expand the reach of ICD technology as we know it today,” said Kucheman, who plans to use the device to increase the $6.2 billion market and take sales from competitors.

Boston Scientific rose less than 1 percent to $5.95 at the close of New York trading. The device maker’s shares have fallen 24 percent in the past 12 months.

Earnings Effect

Boston Scientific plans to pay for the acquisition, which may close in the second or third quarter of 2012, from current cash flow. The purchase will reduce earnings per share by about 1 cent a share on an adjusted basis in 2012 and will break even in 2013, the year Boston Scientific expects the technology to win U.S. approval, the company said.

“The weak link of defibrillator systems to date has been the lead that goes into the heart,” Ken Stein, chief medical officer for Boston Scientific’s cardiac rhythm management group, said today. “The heart beats approximately 100,000 times a day. That’s a lot of mechanical stress. If you are a young patient, you may need that wire to function normally for 30 years.”

The S-ICD system is approved in Europe and sold in several countries around the world, with more than 1,000 patients getting the devices. Closely held Cameron, based in San Clemente, California, applied for U.S. approval in December.

Niche Product

While the technology will bolster Boston Scientific’s defibrillator portfolio, the first version may be a niche product because of physical and technical limitations, said Larry Biegelsen, an analyst at Wells Fargo Securities in New York, in a note to clients. The defibrillator itself is larger than rival models and it doesn’t provide pacing for the heart, something many older patients need, he said.

“Many younger patients do not require these therapies and therefore we see this being the primary initial target patient population,” he said. “This device will improve the company’s visibility in many U.S. accounts and will be valuable product in emerging markets because of its relative ease of implant.”

Boston Scientific has made 13 acquisitions in the last 5 years, with an average disclosed size of $81.5 million, according to data compiled by Bloomberg. The largest during this period was its 2010 purchase of Asthmatx Inc. for $193.5 million, the data show.

The Cameron defibrillator “represents a new category of rhythm management devices that is unlike anything available today,” Kenneth Ellenbogen, director of the electrophysiology Laboratory at the Medical College of Virginia in Richmond, said in the statement. “This system provides physicians with a new alternative in the treatment of patients at risk for sudden cardiac arrest and should become first-line therapy for patients who may benefit from not having a lead in the heart.”

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net; Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Best LBO Ever
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus